Liver cancer: time to evolve trial design after everolimus failure.
about
Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinomaAngiogenesis Inhibitors for the Treatment of Hepatocellular CarcinomaPrognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration, and invasion of human hepatocellular carcinoma.Personalized management of hepatocellular carcinoma based on molecular information: future prospects.Long non-coding RNA AOC4P suppresses hepatocellular carcinoma metastasis by enhancing vimentin degradation and inhibiting epithelial-mesenchymal transitionLong noncoding RNA CPS1-IT1 suppresses the metastasis of hepatocellular carcinoma by regulating HIF-1α activity and inhibiting epithelial-mesenchymal transition.MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.Novel drugs in clinical development for hepatocellular carcinoma.Hepatocyte nuclear factor 1α suppresses steatosis-associated liver cancer by inhibiting PPARγ transcription.Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cellsMelatonin suppresses hepatocellular carcinoma progression via lncRNA-CPS1-IT-mediated HIF-1α inactivation.HIF-2α activated lncRNA NEAT1 promotes hepatocellular carcinoma cell invasion and metastasis by affecting the epithelial-mesenchymal transition.Corylin Suppresses Hepatocellular Carcinoma Progression via the Inhibition of Epithelial-Mesenchymal Transition, Mediated by Long Noncoding RNA GAS5.Multimodality Molecular Imaging-Guided Tumor Border Delineation and Photothermal Therapy Analysis Based on Graphene Oxide-Conjugated Gold Nanoparticles Chelated with Gd.
P2860
Q26766689-9A6F747A-E4E9-4AC6-A37F-12DC53678488Q28070762-5BDE1EA7-C7FB-4F0E-B6AC-0FE644D2B9D9Q28075305-0058FBEE-D291-43F3-9ED1-DFA438C3E406Q35775787-8037E915-41CE-4840-93B5-6580F109D8BCQ35881575-73E517E8-CAD3-42F8-8F3C-274AEDA414F9Q36414180-75FCD020-7A45-4F10-AF9A-35B83F8BA642Q37536645-0EE288BF-10C0-417F-B532-68B8B4B3A99AQ38444096-66F78E4E-265F-4E76-97CC-0D0761253B64Q38537138-D1CE0765-9D56-49EF-B7B4-08CB4D3D6FEDQ42036894-07854A29-28D3-4EDF-8EA0-2D05BDAD31BFQ42654709-6B2FF744-1C0D-471E-B4DC-002D581DFC1AQ45394478-DAFE98C7-3052-49A8-A48D-ED0EDBCC651DQ48089437-2296E85B-70A7-4D1C-ADBD-F02B36778E66Q48141205-26CC0818-71BD-4748-8272-78122F5BD94AQ55344409-EAEAB037-F9DC-4AFE-9289-1FCFB9E77799
P2860
Liver cancer: time to evolve trial design after everolimus failure.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Liver cancer: time to evolve trial design after everolimus failure.
@en
Liver cancer: time to evolve trial design after everolimus failure.
@nl
type
label
Liver cancer: time to evolve trial design after everolimus failure.
@en
Liver cancer: time to evolve trial design after everolimus failure.
@nl
prefLabel
Liver cancer: time to evolve trial design after everolimus failure.
@en
Liver cancer: time to evolve trial design after everolimus failure.
@nl
P2860
P1476
Liver cancer: time to evolve trial design after everolimus failure.
@en
P2860
P304
P356
10.1038/NRCLINONC.2014.136
P407
P577
2014-08-05T00:00:00Z